The LanthaScreen™ LRRK2 G2019S [pSer935] Cellular Assay Kit combines the flexibility of the BacMam gene delivery system with the robustness and power of our LanthaScreen™ TR-FRET technology. It allows researchers to interrogate phosphorylation at serine 935 on a disease-relevant mutant (G2019S) Leucine-Rich Repeat Kinase-2 (LRRK2) protein in a variety of cell backgrounds to identify LRRK2 kinase inhibitors.

This assay format provides a convenient tool for the expression of G2019S LRRK2-GFP fusion protein in the cell background of your choice. The resulting cellular assay can be used to identify LRRK2 G2019S inhibitors, aiding in Parkinson's disease and other research focuses.

This kit provides enough material to evaluate the technology in a 384-well plate; larger sizes of all reagents are available separately.

The kit includes:

• LanthaScreen™ Tb-anti-LRRK2 [pSer935] Antibody, 5 μg
• BacMam LRRK2-GFP G2019S Reagent, 5 × 1 mL
• LanthaScreen™ 6x Lysis Buffer, 6 mL
• Instrument Control Terbium TR-FRET kit

A kit for interrogating wild-type LRRK2 protein is also available.

Benefits of this assay include:

• More Physiologically Relevant: cell-based LRRK2 kinase activity and choice of cell background
• More Convenient: compatible with High Throughput Screening (HTS); LanthaScreen™ technology reduces interference and noise
• Disease Relevant: screen compound libraries for Parkinson's disease-relevant molecules

More Physiologically Relevant
The LanthaScreen™ Tb-Anti-LRRK2 [pSer935] Antibody allows the investigation of phosphorylation at serine 935 on LRRK2 protein kinase. When paired with LRRK2 BacMam reagents, you have the freedom to choose the cellular background for your assay, including primary cells. This enables screening for potential inhibitors of LRRK2 proteins in their natural complexes in a physiologically relevant cell type.

More Convenient
Assays are run in a fully homogenous, addition-only format without any of the washing, lysate transfer, or separation procedures required for traditional methods such as western blotting and ELISA, making this assay ideal for HTS applications. The LanthaScreen™ technology provides all of the advantages of TR-FRET ratiometric detection, including reduced data noise, less interference from fluorescent compounds, and high sensitivity, which results in the use of fewer cells than traditional Western or ELISA methods.

Disease Relevant
The LanthaScreen™ Tb-Anti-LRRK2 [pSer935] Antibody can be used by Parkinson's and other disease researchers to perform HTS, cell-based assays to generate inhibition curves (IC50) for their compound libraries. This will aid drug discovery efforts by reducing the time to results from 4 hrs to typically 1.5 hrs compared to alternative ELISAs.

For Research Use Only. Not intended for animal or human diagnostic or therapeutic use.

Related Links:
• LRRK2 tools for advancing Parkinson's disease research
• Kinase protein portfolio
• LanthaScreen™ Eu Kinase Binding Assay
• LanthaScreen™ Activity Assay
• Learn More About BacMam Technology